Company Encyclopedia
View More
name
Citius Oncology
CTOR.US
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey.
1.945 T
CTOR.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries

    Citius Oncology Inc :CITIUS ONCOLOGY EXPANDS LYMPHIR™ DISTRIBUTION TO TURKEY AND MIDDLE EAST COUNTRIES THROUGH EXCLUSIVE AGREEMENT WITH ER-KIMCITIUS ONCOLOGY INC - ER-KIM TO BE EXCLUSIVE DISTRIBUTOR OF LYMPHIR IN TURKEY AND GCC

    Reuters·
    US
    CTOR
    -3.78%
    Reuters·
    US
    CTOR
    -3.78%

    08:37 ET Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

    Citius Oncology has entered an exclusive distribution agreement with Er-Kim for LYMPHIR in Turkey and key GCC countries. This expands LYMPHIR's availability to 19 markets outside the U.S. LYMPHIR is approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma. Er-Kim will handle sales, marketing, and reimbursement in the specified regions. This partnership is part of Citius Oncology's strategy to broaden access to innovative oncology therapies globally.

    prnewswire·
    US
    CTOR
    -3.78%
    prnewswire·
    US
    CTOR
    -3.78%

    Healthcare Stocks Reverse Some Recent Gains -- Healthcare Roundup

    Healthcare stocks are underperforming as Wall Street reverses Black Friday gains. Citius Oncology shares rose after launching Lymphir for a rare skin cancer. Vaccine makers' shares fell due to an FDA memo linking COVID-19 mRNA vaccines to myocarditis deaths in children. Eli Lilly reduced prices for Zepbound drug vials on its direct-to-consumer platform.

    marketscreener·
    US
    LLY
    -0.21%
    US
    CTOR
    -3.78%
    marketscreener·
    US
    LLY
    -0.21%
    US
    CTOR
    -3.78%

    Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

    Citius Pharmaceuticals Inc. has announced the launch of LYMPHIR, a treatment for cutaneous T-cell lymphoma, marking its first marketed product by Citius Oncology. The company also highlighted other development programs, including Mino-Lok® and Halo-Lido, which have shown positive trial results. Citius Oncology, a majority-owned subsidiary, operates under a shared management agreement with Citius Pharmaceuticals to enhance operational efficiency. This update was published on December 1, 2025.

    Reuters·
    US
    CTOR
    -3.78%
    US
    CTXR
    -3.20%
    Reuters·
    US
    CTOR
    -3.78%
    US
    CTXR
    -3.20%

    Citius Oncology shares are trading higher after the company announced the commercial launch of LYMPHIR, FDA-Approved IL-2 receptor-directed fusion protein, for the treatment of adult patients with r/r Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.

    benzinga_article·
    US
    CTOR
    -3.78%
    benzinga_article·
    US
    CTOR
    -3.78%
    © 2025 Longbridge｜Disclaimer